Susanna Naggie is an Infectious Disease physician affiliated with Duke University. OpenAlex indexes 230 publications with 6,670 citations (h-index 44); ClinicalTrials.gov lists 11 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2100 Erwin Rd
Durham, NC 277100001
Telephone
919-684-8111Registry record last updated 8 Jun 2009.
Clinical trials
- Combating Related Epidemics in HCV
Sponsor: Duke University
- ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
Sponsor: Susanna Naggie, MD
- ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)
Sponsor: Susanna Naggie, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
70.2%Statin28.1%Atorvastatin Calcium100%Part D<11 patientsCalcium channel blocker22.8%Amlodipine Besylate100%Part D<11 patients+ 2 more classes in this area
Anti-infectives
20.2%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor20.2%Isentress52%Tivicay48%Part D<11 patientsGenitourinary & hormones
9.6%alpha-Adrenergic Blocker9.6%Tamsulosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
12 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States
Alimentary Pharmacology & Therapeutics
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Califf, MD
Duke University
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
John Perfect, MD
Duke University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”